Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Recruiting
Phase 2
Interventional Study
Preeclampsia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 50
- Sex
- Female
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 14 (estimated)
- Sponsor
- Mayo Clinic · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Individuals with \< 34 0/7 weeks of gestation.
* Individuals with severe preeclampsia or HELLP features.
Exclusion Criteria:
* Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
* Individuals with non-reassuring fetal status requiring del…
Contacts
Gonzalez Suarez
507-284-2511
CONTACT